Arginine Silicate Inositol Complex for Bone and Vascular Health
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing chronic diseases such as atherosclerosis, osteoporosis, and metabolic syndrome are inadequate, as they often require rigid lifestyle and dietary changes, and existing treatments for conditions like atherosclerosis and osteoporosis do not fully prevent or reverse these diseases.
Innovation Solution
Administration of an arginine silicate inositol complex, which is a bioavailable form of silicon and arginine, to promote bone and cartilage health, improve vascular function, and reduce inflammatory markers, thereby addressing the underlying biochemical markers of these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lifestyle and dietary changes are prescribed to prevent and treat chronic diseases, then health outcomes may improve, but the rigid requirements of these regimens reduce compliance and effectiveness
Solution Approach 1:
The patent changes the biochemical parameters of the body by administering arginine silicate inositol complex, which modifies metabolic pathways and biochemical markers to prevent and treat chronic diseases without requiring rigid lifestyle changes. This approach transforms the treatment paradigm from behavioral modification to biochemical modulation.
Solution Approach 2:
The arginine silicate inositol complex acts as an intermediary substance that mediates between the patient and the disease process. It provides the biochemical building blocks and signaling molecules needed for disease prevention and treatment, eliminating the need for direct behavioral intervention and its associated compliance challenges.
2Reliability
If current treatments for atherosclerosis and other chronic diseases are used, then some disease progression can be retarded, but the treatments are not entirely satisfactory and do not fully prevent or reverse these diseases
Solution Approach 1:
The patent applies preliminary action by providing the biochemical building blocks (arginine, silicate, inositol) before disease progression occurs. This preventive approach ensures that the body has the necessary components to maintain healthy vascular function, bone density, and metabolic parameters, thereby preventing disease rather than merely treating it after onset.
Solution Approach 2:
The arginine silicate inositol complex functions as a composite biochemical material that combines multiple beneficial substances in a single formulation. This composite approach provides synergistic effects that enhance disease prevention and reversal capabilities compared to single-substance treatments, addressing the insufficiency of current monotherapy approaches.
3Reliability
If silicon compounds are administered to inhibit cholesterol-induced intimal hyperplasia, then atherosclerosis progression is retarded, but the biochemical mechanism by which silicon achieves this effect is unknown
Solution Approach 1:
The arginine silicate inositol complex serves as an intermediary that bridges the gap between silicon administration and atherosclerosis inhibition. By combining silicon with arginine and inositol, the complex provides a complete biochemical pathway that includes collagen synthesis stimulation, vascular endothelium protection, and metabolic regulation, thereby elucidating the mechanism while maintaining the therapeutic effect.
Solution Approach 2:
The composite arginine silicate inositol complex integrates multiple biochemical functions into a single substance. This composite formulation not only provides the atherosclerosis-inhibiting effects of silicon but also incorporates arginine for nitric oxide production and inositol for cellular signaling, thereby comprehensively explaining the biochemical mechanism through the combined actions of its components.
Data Source
AI summary
A method for preventing and treating a variety of disease states and disorders is provided, comprising the administration of an arginine silicate inositol complex to an individual in the presence of medical therapy or absence of medical therapy. Examples of said disease states and disorders include bone and cartilage disorders and cardiovascular disease and its associated micro and macro vascular complications including infections and inflammation of all these diseases in combination or without. Advantageously, the amount of arginine silicate inositol complex administered per day is between about 2 mg/Kg body weight to 2,500 mg/Kg body weight or from a low dose to a higher dose to observe normal metabolic functions and healthy and the delivery is parenteral, oral or intravenous or topical by solid or liquid or both.